Welcome at the BIO-TECHNOPARK® Schlieren-Zurich

The Swiss Federal Institute of Technology Zurich (ETH) and the University of Zurich are flagging up an impressive number of spin-off establishments in the Life Sciences. Experience shows that start-up firms locate in the vicinity of their particular knowledge base. There is a healthy spread of firms at varying stages of business development in Schlieren, which range from recent start-ups to global players. In 2003 these firms joined forces in the non-profit organization formerly named Biotech Center Zurich with the owner of the Wagi site, the town of Schlieren and the Canton of Zurich’s Department for Economic Development (Standortförderung) in order to simplify both their internal and external communication and to identify and maximize synergies. 

Currently the Centre has more than 40 member organizations i.e. life science business start-ups and the University Zurich and the University Hospital Zurich with almost 20 clinics, institutes and research groups.

BIO-TECHNOPARK® Schlieren-Zurich hit the headlines with the sale of the young start-up Glycart to Roche in 2005, the takeover of ESBATech by the Novartis company Alcon in 2009, the acquisition of Covagen by Cilag International and the IPO of Molecular Partners in 2014, and the acquisitions of Redvax and Glycovaxyn by Pfizer and GSK, respectively in 2015. Furthermore, Roche gained FDA approval with breakthrough therapy designation for its chronic lymphocytic leukemia agent Gazyva, which was discovered at Roche Glycart in Schlieren.

In close collaboration with the other stakeholders in the field of life sciences, as well as regional and national start-up support bodies, the BIO-TECHNOPARK® Schlieren-Zurich provides a variety of services in the field of start-up support.

The majority of the life science companies collaborating in the BIO-TECHNOPARK® Schlieren-Zurich are to be found on the Wagi site in Schlieren.

Sophisticated Laboratory Buildings

Last update:  2th of Dezember, 2015